clinical trial · NCT07011004
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseCytokine Induced Memory-Like Natural Killer CellsAtezolizumbCIML-NK cell therapy
brief summary
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
started
May 30, 2025
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Apr 9, 2026
official title
Phase I Study of Cytokine Induced Memory-Like Natural Killer Cells Combined With Atezolizumb in Subjects With Relapsed or Refractory Acute Myelogenous Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol